Our team focuses on DM-sensitive antigens as promising targets for selective GvL effects without GvH. On the basis of successfully isolated leukemia-reactive CD4+ T-cell clones, we are now advancing their clinical translation into scalable, GMP-grade cellular therapies. Furthermore, based on our preliminary post-ASCT data suggesting a link between GVHD and T-cell responses to DM-resistant antigens, our future studies will aim to further clarify this relationship.

As a driven early-career scientist, I investigate T-cell and antigen dynamics across diverse disease settings. By combining my background as a pharmacist with hands-on GMP expertise in advanced T-cell therapies, I aim to bridge the gap between bench and bedside and accelerate the translation of promising treatments into clinical practice.